Valganciclovir for congenital CMV-associated hearing loss
Also known as: Valganciclovir, Valcyte, Valganciclovirhydrochloride, Rovalcyte, Oral valganciclovir, Simple Syrup placebo comparator, Simple Syrup, simple-syrup, Sucrose Water, ValEAR Trial, CONCERT, CONCERT 2, GANCIMVEAR, NCT02005822, NCT02606266, NCT03107871, NCT01649869, NCT01655212
Multiple non-industry cCMV hearing-loss study sponsors
Oral valganciclovir, a ganciclovir prodrug antiviral, evaluated to suppress congenital cytomegalovirus replication and reduce or stabilize CMV-associated sensorineural hearing-loss progression in infants and young children.
Normalized a generated generic-drug cluster covering non-industry/NIH/academic studies of oral valganciclovir for congenital cytomegalovirus-associated sensorineural hearing loss. Genentech is listed as an industry collaborator in ValEAR, but the hearing-loss studies are not Genentech-sponsored pipeline programs, so this record is not marked industry-sponsored. The generated Simple Syrup row was collapsed because it is the placebo comparator arm in ValEAR, not a separate therapeutic program. Most linked studies are completed or terminated; ValEAR remains listed as active-not-recruiting in the public registry despite stale anticipated completion dates, so the public status is retained as Active with a QA caveat.